ATE531392T1 - Promotoren mit endothelzellenspezifität und verfahren zu deren anwendung zur steuerung der angiogenese - Google Patents

Promotoren mit endothelzellenspezifität und verfahren zu deren anwendung zur steuerung der angiogenese

Info

Publication number
ATE531392T1
ATE531392T1 AT09168899T AT09168899T ATE531392T1 AT E531392 T1 ATE531392 T1 AT E531392T1 AT 09168899 T AT09168899 T AT 09168899T AT 09168899 T AT09168899 T AT 09168899T AT E531392 T1 ATE531392 T1 AT E531392T1
Authority
AT
Austria
Prior art keywords
angiogenesis
endothelial cell
promotors
controll
subject
Prior art date
Application number
AT09168899T
Other languages
English (en)
Inventor
Dror Harats
Shoshana Greenberger
Eyal Breitbart
Livnat Bangio
Michael Peled
Original Assignee
Vascular Biogenics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vascular Biogenics Ltd filed Critical Vascular Biogenics Ltd
Application granted granted Critical
Publication of ATE531392T1 publication Critical patent/ATE531392T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/49—Platelet-derived growth factor [PDGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • C07K14/503—Fibroblast growth factor [FGF] basic FGF [bFGF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57536—Endothelin, vasoactive intestinal contractor [VIC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/108—Plasmid DNA episomal vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
    • C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/30—Vector systems having a special element relevant for transcription being an enhancer not forming part of the promoter region
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
    • C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
AT09168899T 2004-11-14 2005-11-14 Promotoren mit endothelzellenspezifität und verfahren zu deren anwendung zur steuerung der angiogenese ATE531392T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/988,487 US8071740B2 (en) 2000-11-17 2004-11-14 Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis

Publications (1)

Publication Number Publication Date
ATE531392T1 true ATE531392T1 (de) 2011-11-15

Family

ID=36336885

Family Applications (1)

Application Number Title Priority Date Filing Date
AT09168899T ATE531392T1 (de) 2004-11-14 2005-11-14 Promotoren mit endothelzellenspezifität und verfahren zu deren anwendung zur steuerung der angiogenese

Country Status (14)

Country Link
US (5) US8071740B2 (de)
EP (4) EP1814897A4 (de)
JP (3) JP2008519596A (de)
KR (3) KR101522309B1 (de)
CN (2) CN102698287B (de)
AT (1) ATE531392T1 (de)
AU (1) AU2005303385B2 (de)
CA (2) CA2587469C (de)
IL (1) IL211489A (de)
MX (1) MX2007005783A (de)
NZ (2) NZ580289A (de)
SG (1) SG171581A1 (de)
WO (1) WO2006051545A2 (de)
ZA (1) ZA200704687B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US20070286845A1 (en) * 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) * 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
CN101570764A (zh) * 2001-10-19 2009-11-04 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
WO2007035451A2 (en) * 2005-09-16 2007-03-29 The Board Of Trustees Of The Leland Stanford Junior University Methods of modulating angiogenesis and screening compounds for activity in modulating angiogenesis
WO2008108890A2 (en) * 2006-10-18 2008-09-12 University Of Rochester Conditionally replicating viruses for cancer therapy
US9320738B2 (en) * 2008-06-30 2016-04-26 Tocagen Inc. Formulations of 5-fluorocytosine and uses thereof
AU2013205004B2 (en) * 2008-06-30 2015-08-27 Tocagen Inc. Formulations of 5-fluorocytosine and Uses Thereof
US20110172293A1 (en) 2008-07-08 2011-07-14 Fish Jason E Methods and Compositions for Modulating Angiogenesis
SG10201500013SA (en) 2010-01-05 2015-03-30 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
NZ601325A (en) * 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
ES2703428T3 (es) * 2010-02-25 2019-03-08 Abt Holding Co Modulación de la angiogénesis
EP2591093B1 (de) 2010-07-07 2018-11-28 FUJIFILM Cellular Dynamics, Inc. Endothelzellenproduktion durch programmierung
CA2827645C (en) * 2011-02-18 2021-11-02 The Uab Research Foundation Enhanced therapeutic usage of a purine nucleoside phosphorylase or nucleoside hydrolase prodrug related applications
CN107488233A (zh) * 2011-06-02 2017-12-19 台北荣民总医院 治疗感染性与恶性疾病的标靶化学治疗药物的形成方法
IN2014DN06898A (de) * 2012-03-14 2015-05-15 Salk Inst For Biological Studi
NZ707336A (en) 2012-10-17 2019-01-25 Vascular Biogenics Ltd Treatment methods using adenovirus
ES2774964T3 (es) 2013-02-04 2020-07-23 Vascular Biogenics Ltd Métodos para inducir la capacidad de respuesta a un agente antiangiogénico
WO2015048468A1 (en) 2013-09-27 2015-04-02 Mevion Medical Systems, Inc. Particle beam scanning
US10675487B2 (en) 2013-12-20 2020-06-09 Mevion Medical Systems, Inc. Energy degrader enabling high-speed energy switching
US9962560B2 (en) 2013-12-20 2018-05-08 Mevion Medical Systems, Inc. Collimator and energy degrader
US9661736B2 (en) 2014-02-20 2017-05-23 Mevion Medical Systems, Inc. Scanning system for a particle therapy system
ES2764453T3 (es) * 2015-03-17 2020-06-03 Univ Brussel Vrije Sistemas de expresión específica de hígado optimizados para FVIII y FIX
US10786689B2 (en) 2015-11-10 2020-09-29 Mevion Medical Systems, Inc. Adaptive aperture
CN109803723B (zh) 2016-07-08 2021-05-14 迈胜医疗设备有限公司 一种粒子疗法系统
US11103730B2 (en) 2017-02-23 2021-08-31 Mevion Medical Systems, Inc. Automated treatment in particle therapy
EP3645111B1 (de) 2017-06-30 2025-04-23 Mevion Medical Systems, Inc. Unter verwendung von linearmotoren gesteuerter, konfigurierbarer kollimator
WO2019077593A1 (en) 2017-10-20 2019-04-25 Vascular Biogenics Ltd. DIAGNOSTIC METHODS FOR ANTI-ANGIOGENIC AGENT TREATMENT
WO2019167995A1 (ja) * 2018-02-28 2019-09-06 国立大学法人東京医科歯科大学 虚血病変部位特異的な遺伝子治療法
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
US11291861B2 (en) 2019-03-08 2022-04-05 Mevion Medical Systems, Inc. Delivery of radiation by column and generating a treatment plan therefor
KR20210139329A (ko) 2019-03-13 2021-11-22 바스큘라 바이오제닉스 리미티드 항종양 요법의 방법
WO2020208612A1 (en) 2019-04-12 2020-10-15 Vascular Biogenics Ltd. Methods of anti-tumor therapy
CN110714028B (zh) * 2019-11-04 2021-08-31 中国人民解放军第四军医大学 可控性上调Ang-(1-7)靶向性防治低氧性肺动脉高压的表达载体
EP4192960A4 (de) * 2020-08-05 2024-11-27 Spacecraft Seven, LLC Adeno-assoziierter viraler vektor zur glut1-expression und verwendungen davon

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (nl) 1971-02-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen.
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
NL154599B (nl) 1970-12-28 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (nl) 1972-05-11 1983-06-01 Akzo Nv Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
CH642665A5 (en) 1979-02-08 1984-04-30 Rudolf Berchtold Process for the preparation of 1-(omega-carboxyalkyl)-2-alkyl- glycero-3-phosphatides
US4329302A (en) 1980-06-27 1982-05-11 Board Of Regents, The University Of Texas System Synthetic phosphoglycerides possessing platelet activating properties
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US4410237A (en) 1980-09-26 1983-10-18 Massachusetts Institute Of Technology Method and apparatus for shaping electromagnetic beams
DE3307925A1 (de) 1983-03-05 1984-09-06 A. Nattermann & Cie GmbH, 5000 Köln Neue 0-acyl-alkandiol-phospholipide, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
US4614796A (en) 1983-03-25 1986-09-30 Nippon Shinyaku Co., Ltd. Liposome and method of manufacture therefor
JPS60100544A (ja) 1983-11-08 1985-06-04 Ono Pharmaceut Co Ltd 新規なグリセリン誘導体，その製造方法及びその誘導体を含有する薬剤
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4710579A (en) 1984-11-09 1987-12-01 Takeda Chemical Industries, Ltd. 2-(acetoacetyloxy)-3-(octadecyloxy)propyl-3-trimethylammoniopropyl phosphate or a pharmaceutically acceptable salt thereof
US4827011A (en) 1984-12-10 1989-05-02 American Cyanamid Company Antihypertensive phosphate derivatives
JP2528107B2 (ja) 1985-03-15 1996-08-28 サマ−トン，ジエ−ムス ポリヌクレオチド測定試薬と方法
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4711512A (en) 1985-07-12 1987-12-08 Environmental Research Institute Of Michigan Compact head-up display
CA1293663C (en) * 1986-01-06 1991-12-31 David Christopher Auth Transluminal microdissection device
WO1987005904A1 (en) 1986-03-24 1987-10-08 The University Of Sydney Antigenic analogues of platelet activating factor (paf)
US5314407A (en) * 1986-11-14 1994-05-24 Heart Technology, Inc. Clinically practical rotational angioplasty system
US4866042A (en) 1987-11-18 1989-09-12 Neuwelt Edward A Method for the delivery of genetic material across the blood brain barrier
DE3807123A1 (de) 1988-03-04 1989-09-14 Boehringer Mannheim Gmbh Substrate fuer phospholipasen
DE8904026U1 (de) * 1988-04-20 1989-05-24 Schneider (Europe) AG, Zürich Katheter zum Rekanalisieren von verengten Gefäßen
DE3821544C2 (de) * 1988-06-25 1994-04-28 H Prof Dr Med Just Dilatationskatheter
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5087244A (en) * 1989-01-31 1992-02-11 C. R. Bard, Inc. Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US4994033A (en) * 1989-05-25 1991-02-19 Schneider (Usa) Inc. Intravascular drug delivery dilatation catheter
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US6337209B1 (en) * 1992-02-26 2002-01-08 Glaxo Wellcome Inc. Molecular constructs containing a carcinoembryonic antigen regulatory sequence
US5237451A (en) 1989-11-17 1993-08-17 Minnesota Mining And Manufacturing Company Beam shaping system using diffraction
US5082629A (en) 1989-12-29 1992-01-21 The Board Of The University Of Washington Thin-film spectroscopic sensor
US5049132A (en) * 1990-01-08 1991-09-17 Cordis Corporation Balloon catheter for delivering therapeutic agents
US5053041A (en) * 1990-03-12 1991-10-01 Ansari Shapoor S Vessel holder
ES2019552A6 (es) 1990-04-11 1991-06-16 Menarini Lab Procedimiento para la preparacion de glicerofosfolipidos.
US5364393A (en) * 1990-07-02 1994-11-15 Heart Technology, Inc. Tissue dissipative recanalization catheter
US5180366A (en) * 1990-10-10 1993-01-19 Woods W T Apparatus and method for angioplasty and for preventing re-stenosis
EP0575518A1 (de) 1991-03-06 1993-12-29 Board Of Regents, The University Of Texas System Verfahren und zusammensetzungen fuer die selektive hemmung von genexpression
US5213576A (en) * 1991-06-11 1993-05-25 Cordis Corporation Therapeutic porous balloon catheter
US5766151A (en) * 1991-07-16 1998-06-16 Heartport, Inc. Endovascular system for arresting the heart
US5224198A (en) 1991-09-30 1993-06-29 Motorola, Inc. Waveguide virtual image display
US5306250A (en) * 1992-04-02 1994-04-26 Indiana University Foundation Method and apparatus for intravascular drug delivery
US5368566A (en) * 1992-04-29 1994-11-29 Cardiovascular Dynamics, Inc. Delivery and temporary stent catheter having a reinforced perfusion lumen
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5447497A (en) * 1992-08-06 1995-09-05 Scimed Life Systems, Inc Balloon catheter having nonlinear compliance curve and method of using
US5569189A (en) * 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5336178A (en) * 1992-11-02 1994-08-09 Localmed, Inc. Intravascular catheter with infusion array
US5614502A (en) * 1993-01-15 1997-03-25 The General Hospital Corporation High-pressure impulse transient drug delivery for the treatment of proliferative diseases
WO1994021320A1 (en) * 1993-03-15 1994-09-29 Advanced Cardiovascular Systems, Inc. Fluid delivery catheter
JP3623250B2 (ja) 1993-06-23 2005-02-23 オリンパス株式会社 映像表示装置
DE4324218A1 (de) * 1993-07-19 1995-01-26 Bavaria Med Tech Manschettenkatheter
US5631236A (en) 1993-08-26 1997-05-20 Baylor College Of Medicine Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk
US5635385A (en) 1993-09-15 1997-06-03 Temple University-Of The Commonwealth System Of Higher Education Multi-unit ribozyme inhibition of oncogene gene expression
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
US6579697B1 (en) 1995-05-11 2003-06-17 Yeda Research And Development Co. Ltd. Modulator of TNF/NGF superfamily receptors and soluble oligomeric TNF/NGF superfamily receptors
JPH07326065A (ja) 1994-05-27 1995-12-12 Hitachi Ltd 光情報処理装置
US8715645B2 (en) 1994-05-27 2014-05-06 The Regents Of The University Of Colorado Viral vectors encoding apoptosis-inducing proteins and methods for making and using the same
US5906827A (en) 1994-06-03 1999-05-25 Creative Biomolecules, Inc. Matrix for the manufacture of autogenous replacement body parts
US5747340A (en) * 1994-06-03 1998-05-05 Syntex (U.S.A.) Inc. Targeted gene expression using preproendothelin-1 promoters
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
EP0781138B1 (de) 1994-08-29 2008-05-21 Wake Forest University Lipid-analoge zur behandlung von viralen infektionen
US5734039A (en) 1994-09-15 1998-03-31 Thomas Jefferson University Antisense oligonucleotides targeting cooperating oncogenes
US5506929A (en) 1994-10-19 1996-04-09 Clio Technologies, Inc. Light expanding system for producing a linear or planar light beam from a point-like light source
US6638762B1 (en) * 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5712149A (en) 1995-02-03 1998-01-27 Cell Genesys, Inc. Chimeric receptor molecules for delivery of co-stimulatory signals
US5660855A (en) 1995-02-10 1997-08-26 California Institute Of Technology Lipid constructs for targeting to vascular smooth muscle tissue
US5792453A (en) * 1995-02-28 1998-08-11 The Regents Of The University Of California Gene transfer-mediated angiogenesis therapy
US5730723A (en) * 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US6254862B1 (en) 1997-03-03 2001-07-03 Calydon, Inc. Adenovirus vectors specific for cells expressing alpha-fetoprotein and methods of use thereof
US5746716A (en) * 1995-07-10 1998-05-05 Interventional Technologies Inc. Catheter for injecting fluid medication into an arterial wall
MXPA98002791A (es) * 1995-10-11 2004-09-07 Esperion Luv Dev Inc Composiciones liposomales y metodos para usarlas.
US5916763A (en) 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
US5761477A (en) * 1995-12-04 1998-06-02 Microsoft Corporation Methods for safe and efficient implementations of virtual machines
US6825980B2 (en) 1995-12-18 2004-11-30 Metrologic Instruments, Inc. DOE-based systems and devices for producing laser beams having modified beam characteristics
AU3583797A (en) 1996-06-28 1998-01-21 Regents Of The University Of California, The Enhancement of cancer cell death
US6200751B1 (en) 1996-11-08 2001-03-13 Oklahoma Medical Research Foundation Endothelial specific expression regulated by EPCR control elements
NZ336381A (en) * 1996-12-30 2000-11-24 Battelle Memorial Institute Formulation and method for treating neoplasms by inhalation
BR9807622A (pt) 1997-02-28 2000-02-15 Boehringer Ingelheim Pharma Apoptose auto-regulada de células inflamatórias por terapia de gene
US6206917B1 (en) 1997-05-02 2001-03-27 St. Jude Medical, Inc. Differential treatment of prosthetic devices
WO1999006563A1 (en) 1997-07-30 1999-02-11 Emory University Novel bone mineralization proteins, dna, vectors, expression systems
US6204055B1 (en) * 1999-04-12 2001-03-20 Isis Pharmaceuticals, Inc. Antisense inhibition of Fas mediated signaling
EP0909532A1 (de) 1997-10-16 1999-04-21 Development Center For Biotechnology Umweltfreundliches poröses Material enthaltend vorteilhafte Nematoden und dessen Herstellung
DE69831589T2 (de) 1997-10-30 2006-06-22 The General Hospital Corp., Boston Zusammenfügung von knorpelmatrizen unter verwendung isolierter chondrozyten
US5882893A (en) * 1997-12-04 1999-03-16 Millennium Pharmaceuticals, Inc. Nucleic acids encoding muscarinic receptors and uses therefor
US6027514A (en) * 1997-12-17 2000-02-22 Fox Hollow Technologies, Inc. Apparatus and method for removing occluding material from body lumens
US6699231B1 (en) * 1997-12-31 2004-03-02 Heartport, Inc. Methods and apparatus for perfusion of isolated tissue structure
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
WO1999052002A1 (en) 1998-04-02 1999-10-14 Elop Electro-Optics Industries Ltd. Holographic optical devices
US6364856B1 (en) * 1998-04-14 2002-04-02 Boston Scientific Corporation Medical device with sponge coating for controlled drug release
JP2002513914A (ja) * 1998-05-07 2002-05-14 ユニバーシティ・オブ・メリーランド， ボルティモア 慢性骨盤痛症候群の診断および治療方法
US6206283B1 (en) * 1998-12-23 2001-03-27 At&T Corp. Method and apparatus for transferring money via a telephone call
US6280411B1 (en) * 1998-05-18 2001-08-28 Scimed Life Systems, Inc. Localized delivery of drug agents
US20030060876A1 (en) * 2000-09-28 2003-03-27 Amir Loshakove Graft delivery system
US6239151B1 (en) * 1998-06-26 2001-05-29 Hoffmann-La Roche Inc. Compounds as inhibitor of tumor necrosis factor alpha release
US6036700A (en) * 1998-07-14 2000-03-14 Ethicon Endo-Surgery, Inc. Surgical anastomosis instrument
EP1100941A2 (de) 1998-07-27 2001-05-23 Valentis Inc. Anti-angiogenesis plasmide und applikationssysteme , und methode für ihre herstellung und verwendung
DE19838837A1 (de) 1998-08-27 2000-03-02 Boehringer Ingelheim Int Zellspezifische Promoter des Entkopplungsproteins 3
US6280414B1 (en) * 1998-09-30 2001-08-28 Medtronic Ave, Inc. Method and apparatus for local delivery of therapeutic agent
JP3622556B2 (ja) 1999-02-23 2005-02-23 セイコーエプソン株式会社 照明光学系および投写型表示装置
US6743196B2 (en) * 1999-03-01 2004-06-01 Coaxia, Inc. Partial aortic occlusion devices and methods for cerebral perfusion augmentation
JP2003501367A (ja) * 1999-06-08 2003-01-14 トランジェーヌ、ソシエテ、アノニム 哺乳類における細胞傷害、特に抗腫瘍または抗ウイルスの治療用の組成物
IL130608A0 (en) * 1999-06-23 2000-06-01 Compugen Ltd Novel nucleic and amino acid sequence
US6545048B1 (en) * 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6638233B2 (en) * 1999-08-19 2003-10-28 Fox Hollow Technologies, Inc. Apparatus and methods for material capture and removal
US6299622B1 (en) * 1999-08-19 2001-10-09 Fox Hollow Technologies, Inc. Atherectomy catheter with aligned imager
US6447525B2 (en) * 1999-08-19 2002-09-10 Fox Hollow Technologies, Inc. Apparatus and methods for removing material from a body lumen
US6348583B1 (en) 1999-08-30 2002-02-19 Bio-Rad Laboratories, Inc. Poly(ether-thioether), poly(ether-sulfoxide) and poly(ether-sulfone) nucleic acids
US6733513B2 (en) * 1999-11-04 2004-05-11 Advanced Bioprosthetic Surfaces, Ltd. Balloon catheter having metal balloon and method of making same
WO2001039744A2 (en) 1999-11-30 2001-06-07 The Arizona Board Of Regents On Behalf Of The University Of Arizona Radiation sensitive liposomes
US6344027B1 (en) * 1999-12-08 2002-02-05 Scimed Life Systems, Inc. Needle-less injection apparatus and method
US6576265B1 (en) 1999-12-22 2003-06-10 Acell, Inc. Tissue regenerative composition, method of making, and method of use thereof
US6376244B1 (en) 1999-12-29 2002-04-23 Children's Medical Center Corporation Methods and compositions for organ decellularization
US6479064B1 (en) 1999-12-29 2002-11-12 Children's Medical Center Corporation Culturing different cell populations on a decellularized natural biostructure for organ reconstruction
US6265216B1 (en) 2000-01-20 2001-07-24 Isis Pharmaceuticals, Inc. Antisense modulation of cot oncogene expression
US6629953B1 (en) * 2000-02-18 2003-10-07 Fox Hollow Technologies, Inc. Methods and devices for removing material from a vascular site
US6866864B2 (en) * 2000-03-20 2005-03-15 Ahmed Mousa Compositions and methods of use in the treatment of angiogenesis and vascular-related disorders
WO2001070175A2 (en) * 2000-03-21 2001-09-27 The University Of Virginia Patent Foundation Osteocalcin promoter directed adenovirus replicaton for therapy
US6652583B2 (en) 2000-04-07 2003-11-25 Rhode Island Hospital Cardiac valve replacement
US6716190B1 (en) * 2000-04-19 2004-04-06 Scimed Life Systems, Inc. Device and methods for the delivery and injection of therapeutic and diagnostic agents to a target site within a body
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
SE0001894D0 (sv) * 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab Medical device
EP1301612A2 (de) * 2000-05-31 2003-04-16 Genvec, Inc. Verfahren und zusammenfassung zur zielrichtung von adenoviralen vektoren
EP1302539A4 (de) * 2000-07-21 2004-10-27 Chiba Prefecture Tumor-spezifische promotoren
IL138766A0 (en) * 2000-09-28 2001-10-31 Cyclo Science Ltd Constant pressure apparatus for the administration of fluids intravenously
JP2002122783A (ja) 2000-10-13 2002-04-26 Olympus Optical Co Ltd 観察光学系及び撮像光学系及びそれを用いた装置
ES2425321T3 (es) * 2000-11-17 2013-10-14 Vascular Biogenics Ltd. Promotores que muestran especificidad por células endoteliales y métodos de utilización de los mismos
US8071740B2 (en) 2000-11-17 2011-12-06 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
AU2003222427B8 (en) * 2000-11-17 2010-04-29 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US20100282634A1 (en) * 2000-11-17 2010-11-11 Dror Harats Promoters Exhibiting Endothelial Cell Specificity and Methods of Using Same for Regulation of Angiogenesis
US7067649B2 (en) 2000-11-17 2006-06-27 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same
US8039261B2 (en) 2000-11-17 2011-10-18 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US20070286845A1 (en) 2000-11-17 2007-12-13 Vascular Biogenics Ltd. Promoters exhibiting endothelial cell specificity and methods of using same for regulation of angiogenesis
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
US6623452B2 (en) * 2000-12-19 2003-09-23 Scimed Life Systems, Inc. Drug delivery catheter having a highly compliant balloon with infusion holes
US6544223B1 (en) * 2001-01-05 2003-04-08 Advanced Cardiovascular Systems, Inc. Balloon catheter for delivering therapeutic agents
CA2436665C (en) 2001-01-29 2012-01-10 Bio-Rad Laboratories, Inc. Nucleic acid derivatives
US20020107504A1 (en) * 2001-02-06 2002-08-08 Gordon Lucas S. Apparatus for local drug delivery in limb
ES2545899T3 (es) 2001-02-14 2015-09-16 Anthrogenesis Corporation Placenta post-parto de mamíferos, su uso y células madre placentarias de la misma
KR20020083737A (ko) 2001-04-30 2002-11-04 삼성전자 주식회사 착용형 디스플레이 시스템
US6438802B1 (en) 2001-06-07 2002-08-27 Randolph Scott Beeman Locking mechanism and method for securely fastening resilient cords and tubing
WO2003000928A2 (en) * 2001-06-25 2003-01-03 Buadbo Aps Methods for identification of cancer cell surface molecules and cancer specific promoters, and therapeutic uses thereof
CN1195056C (zh) * 2001-07-12 2005-03-30 钱其军 一种在肿瘤细胞中特异性增殖及高效表达抗癌基因的重组病毒及其构建方法
KR100453877B1 (ko) * 2001-07-26 2004-10-20 메덱스젠 주식회사 연쇄체화에 의한 면역 글로블린 융합 단백질의 제조 방법 및 이 방법에 의해 제조된 ＴＮＦＲ/Ｆｃ 융합 단백질, 상기 단백질을 코딩하는 ＤＮＡ, 상기 ＤＮＡ를 포함하는벡터, 및 상기 벡터에 의한 형질전환체
WO2003013434A2 (en) 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
US6833955B2 (en) 2001-10-09 2004-12-21 Planop Planar Optics Ltd. Compact two-plane optical device
CN101570764A (zh) * 2001-10-19 2009-11-04 脉管生物生长有限公司 多核苷酸构建体、药物组合物以及靶向的下调血管生成和抗癌的治疗方法
US20040044403A1 (en) 2001-10-30 2004-03-04 Joyce Bischoff Tissue-engineered vascular structures
IL161686A0 (en) * 2001-11-01 2004-09-27 Uab Research Foundation Combinations of antibodies selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and other therapeutic agents
US20030086903A1 (en) * 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
EP2292278B1 (de) 2001-11-16 2013-04-24 Children's Medical Center Corporation Verbesserung der Funktion von Organen
KR100450815B1 (ko) 2002-02-01 2004-10-01 삼성전자주식회사 조명계 및 이를 채용한 프로젝션 디스플레이 장치
US20030180268A1 (en) 2002-02-05 2003-09-25 Anthony Atala Tissue engineered construct for supplementing or replacing a damaged organ
US7247477B2 (en) 2002-04-16 2007-07-24 Technion Research & Development Foundation Ltd. Methods for the in-vitro identification, isolation and differentiation of vasculogenic progenitor cells
US6757105B2 (en) 2002-04-25 2004-06-29 Planop Planar Optics Ltd. Optical device having a wide field-of-view for multicolor images
US7023622B2 (en) 2002-08-06 2006-04-04 Dmetrix, Inc. Miniature microscope objective lens
US6805490B2 (en) 2002-09-30 2004-10-19 Nokia Corporation Method and system for beam expansion in a display device
EP1545627A4 (de) 2002-10-01 2006-12-27 Univ Duke Gezielte tumortherapie durch verwendung von rekombinanten adenovirus-vektoren zur selektiven replikation in hypoxischen tumorregionen
WO2004035616A2 (de) * 2002-10-15 2004-04-29 Per Sonne Holm Adenovirus mit umgekehrter reihenfolge der expression von genen und verwendung davon
JP4245563B2 (ja) 2002-12-26 2009-03-25 三洋電機株式会社 投写型映像表示装置
US7226748B2 (en) * 2003-01-03 2007-06-05 Aurelium Biopharma, Inc. HSC70 directed diagnostics and therapeutics for multidrug resistant neoplastic disease
WO2004113497A2 (en) 2003-06-09 2004-12-29 University Of Florida Gene delivery to tumors
US7184617B2 (en) 2004-03-12 2007-02-27 Matsushita Electric Industrial Co., Ltd. Portable device
US20060190022A1 (en) * 2004-07-14 2006-08-24 By-Pass, Inc. Material delivery system
US20080063656A1 (en) * 2004-08-09 2008-03-13 Emini Emilio A Adenoviral Vector Compositions
US20060056028A1 (en) 2004-09-13 2006-03-16 Wildnauer Kenneth R Apodized diffraction grating with improved dynamic range
US20060194765A1 (en) 2004-11-16 2006-08-31 Garcia Joe G N Methods and compositions using oxidized phospholipids
US7206107B2 (en) 2004-12-13 2007-04-17 Nokia Corporation Method and system for beam expansion in a display device
WO2006079176A1 (en) * 2005-01-28 2006-08-03 Apollo Life Sciences Limited Molecules and chimeric molecules thereof
US8137977B2 (en) 2006-04-24 2012-03-20 Children's Hospital & Research Center At Oakland Lipidomic approaches to determining drug response phenotypes in cardiovascular disease
AU2007280017B2 (en) * 2006-07-31 2012-04-12 Vascular Biogenics Ltd. Polypeptides and polynucleotides encoding same and use thereof in the treatment of medical conditions associated with ischemia
US20080140001A1 (en) * 2006-12-12 2008-06-12 By-Pass Inc. Fluid Delivery Apparatus And Methods
US20100191215A1 (en) * 2007-06-12 2010-07-29 By-Pass ,Inc. Pressure pulse actuating device for delivery systems
KR20090011223A (ko) 2007-07-25 2009-02-02 삼성전자주식회사 방송처리장치 및 그 제어방법
AU2008330093A1 (en) 2007-11-28 2009-06-04 Yeda Research And Development Co., Ltd. Method of delaying the onset of clinically definite multiple sclerosis
TW200935607A (en) * 2008-02-05 2009-08-16 Univ Yuan Ze Ceramic MESFET device and a manufacturing method therefor
US20110083464A1 (en) 2009-10-12 2011-04-14 Craig Kettles Refrigerator with a Pullout Refrigerator Compartment
SG10201500013SA (en) * 2010-01-05 2015-03-30 Vascular Biogenics Ltd Methods for use of a specific anti-angiogenic adenoviral agent
NZ601325A (en) * 2010-01-05 2014-09-26 Vascular Biogenics Ltd Compositions and methods for treating glioblastoma gbm
SG10201500015TA (en) * 2010-01-12 2015-02-27 Vascular Biogenics Ltd Methods of producing adenovirus vectors and viral preparations generated thereby
WO2012052878A1 (en) 2010-10-19 2012-04-26 Vascular Biogenics Ltd. Isolated polynucleotides and nucleic acid constructs for directing expression of a gene-of-interest in cells

Also Published As

Publication number Publication date
HK1143078A1 (en) 2010-12-24
IL211489A (en) 2014-06-30
JP2012010710A (ja) 2012-01-19
WO2006051545A2 (en) 2006-05-18
US8071740B2 (en) 2011-12-06
CA2587469C (en) 2016-02-02
EP2301585B1 (de) 2015-01-07
US20100081193A1 (en) 2010-04-01
CA2913047A1 (en) 2006-05-18
US20050186179A1 (en) 2005-08-25
EP2301586B1 (de) 2012-09-26
KR20130137724A (ko) 2013-12-17
KR20070086209A (ko) 2007-08-27
EP2174668B1 (de) 2011-11-02
US8206743B2 (en) 2012-06-26
SG171581A1 (en) 2011-06-29
EP1814897A2 (de) 2007-08-08
NZ555612A (en) 2009-12-24
JP5728337B2 (ja) 2015-06-03
EP2301586A1 (de) 2011-03-30
ZA200704687B (en) 2008-12-31
US20110129511A1 (en) 2011-06-02
AU2005303385A1 (en) 2006-05-18
NZ580289A (en) 2010-12-24
CN102698287B (zh) 2017-06-13
US20110207985A1 (en) 2011-08-25
EP2174668A3 (de) 2010-06-16
CA2587469A1 (en) 2006-05-18
AU2005303385B2 (en) 2011-08-11
CN101098882A (zh) 2008-01-02
KR20130072263A (ko) 2013-07-01
MX2007005783A (es) 2007-09-11
JP2015057057A (ja) 2015-03-26
EP1814897A4 (de) 2007-11-14
WO2006051545A3 (en) 2006-09-28
KR101522309B1 (ko) 2015-05-21
US8835398B2 (en) 2014-09-16
EP2174668A2 (de) 2010-04-14
KR101313257B1 (ko) 2013-10-16
CN102698287A (zh) 2012-10-03
JP2008519596A (ja) 2008-06-12
US20130011367A1 (en) 2013-01-10
EP2301585A1 (de) 2011-03-30
KR101396454B1 (ko) 2014-05-20

Similar Documents

Publication Publication Date Title
ATE531392T1 (de) Promotoren mit endothelzellenspezifität und verfahren zu deren anwendung zur steuerung der angiogenese
JP2012529436A5 (de)
MA27838A1 (fr) Traitement d'une maladie auto-immune chez un patient presentant une reponse inadequate a un inhibiteur de tnf-alpha
NZ707292A (en) Activin-actrii antagonists and uses for increasing red blood cell levels
EA201391012A1 (ru) Лиганды, связывающиеся с рецепторами tgf-бета типа ii
DK1472344T3 (da) Bakteriofaglysin
TNSN07191A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
EP1548032A4 (de) Kdr-peptide und diese enthaltende impfstoffe
WO2008057459A3 (en) Antagonists of pcsk9
WO2008057457A3 (en) Antagonists of pcsk9
WO2008133647A3 (en) Antagonists of pcsk9
ATE423134T1 (de) Verbesserte sezernierung von neublastin
ATE302267T1 (de) Transgenes kaninchen, dass ein funktionelles menschliches lipoprotein(a) exprimiert
IL183165A (en) Polypeptides derived from the extracellular protein of the trem-1 protein and which can be used as antagonists of the trem-1 protein, preparations containing them and their uses for the preparation of a drug for the treatment of sepsis, septic shock and sepsis-like conditions
ATE551060T1 (de) Zusammensetzungen und verfahren zur behandlung von neovaskulären erkrankungen
EA200901432A1 (ru) Новые аспарагиназы и их применение
JP2015514132A5 (de)
RU2011105821A (ru) Терапевтическое дозирование нейрегулина или его подпоследовательности для лечения или профилактики сердечной недостаточности
JP2013511559A5 (de)
WO2004091490A3 (en) Somatostatin-dopamine chimeric analogs
CY1111941T1 (el) Χρηση ενος μοριου νουκλεϊνικου οξεως το οποιο κωδικοποιει τον τομεα δισιντεγρινης μιας αδαμαλυσινης ως αντι-αγγειογονου, αντι-διεισδυτικου και αντι-μεταστατικου παραγοντα
HRP20050903B1 (hr) Intravenska injekcija ne-neurotoksiäśnih aktivatora plazminogena za tretman kapi
WO2008049098A3 (en) ANTIBODY ANTAGONISTS OF INTERLEUKIN-13 RECEPTOR α1
CY1114254T1 (el) Ενδοφλεβια ενεση μη νευροτοξικων ενεργοποιητων του πλασμινογονου για την αντιμετωπιση του εγκεφαλικου επεισοδιου
RU2006119452A (ru) Рекомбинантный белок, обладающий противораковым действием, кодирующий его ген и его применение